This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singer, F. R. Articles by Bekker, P. J. Search for Related Content PubMed PubMed Citation Articles by Singer, F. R. Articles by Bekker, P. J.

Risedronate, a Highly Effective Oral Agent in the Treatment of Patients with Severe Paget’s Disease¹

John Wayne Cancer Institute (F.R.S.), Santa Monica, California 90404; University of Cincinnati School of Medicine (T.L.C.), Cincinnati, Ohio 45267; and Procter and Gamble Pharmaceuticals (R.A.E., P.J.B.), Cincinnati, Ohio 45242

Thirteen patients with severe Paget’s disease of bone [mean serum alkaline phosphatase (SAP) level 17 times the upper limit of normal] were treated with 30 mg oral risedronate daily for 8 weeks. Patients were followed for 16 weeks without treatment. The change from baseline SAP was the primary end point. Those patients whose SAP levels did not reach the normal range were retreated with 30 mg for another 8 weeks. There was a mean percent decrease in SAP of 77% after the first course of risedronate treatment and 87% after the second course of treatment. All patients who completed the study had a decrease in SAP of at least 77% from the baseline. The urinary hydroxyproline/creatinine level was decreased by 64% and 79%, respectively, during the first and second treatment courses. There were transient asymptomatic decreases in serum calcium and phosphorus levels. The urinary calcium/creatinine ratio also decreased in these patients. Serum intact PTH and 1,25-dihydroxyvitamin D levels increased transiently during risedronate treatment. Oral risedronate was well tolerated by the patients. Only one patient discontinued treatment because of an adverse event (diarrhea) thought to be related to risedronate therapy.

This article has been cited by other articles:

				R. G. G. Russell Bisphosphonates: Mode of Action and Pharmacology Pediatrics, March 1, 2007; 119(Supplement_2): S150 - S162. [Abstract] [Full Text] [PDF]

				R. G. G. RUSSELL Bisphosphonates: From Bench to Bedside Ann. N.Y. Acad. Sci., April 1, 2006; 1068(1): 367 - 401. [Abstract] [Full Text] [PDF]

				I. R. Reid, P. Miller, K. Lyles, W. Fraser, J. P. Brown, Y. Saidi, P. Mesenbrink, G. Su, J. Pak, K. Zelenakas, et al. Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease N. Engl. J. Med., September 1, 2005; 353(9): 898 - 908. [Abstract] [Full Text] [PDF]

				H. D. Menssen, A. Sakalova, A. Fontana, Z. Herrmann, C. Boewer, T. Facon, M. R. Lichinitser, C.R.J. Singer, L. Euller-Ziegler, M. Wetterwald, et al. Effects of Long-Term Intravenous Ibandronate Therapy on Skeletal-Related Events, Survival, and Bone Resorption Markers in Patients With Advanced Multiple Myeloma J. Clin. Oncol., May 1, 2002; 20(9): 2353 - 2359. [Abstract] [Full Text] [PDF]

				C. Crandall Risedronate: A Clinical Review Arch Intern Med, February 12, 2001; 161(3): 353 - 360. [Abstract] [Full Text] [PDF]

				I. Fogelman, C. Ribot, R. Smith, D. Ethgen, E. Sod, and J.-Y. Reginster Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1895 - 1900. [Abstract] [Full Text]